Abstract:e21055 Background: PD-L1 is a recommended biomarker for immunotherapy, but Some patients with high pD-L1 expression had poor clinical response. Considering the inconsistent correlation between PD- L1 expression and ICI efficacy, A more sensitive biomarker is needed to predict immunotherapy efficacy. B-cell lymphoma-2 (BCL2L11/BIM) belongs to the Bcl-2 family and is a key factor promoting apoptosis. BIM deletion polymorphism (BIM- del) may lead to BH3 deletion and thus hinder cell apoptosis. Loss and decreased expression of BIM may lead to resistance to tumor therapy. A study on patients with metastatic melanoma found that the high level of BIM in CD8+ T cells suggests a stronger PD-1 and PD-L1 interaction, which predicts clinical benefit in patients with metastatic melanoma receiving anti-PD-1 therapy.This study aims to evaluate the relationship between BIM deletion and PD-1/PD-L1 inhibitors efficacy in advanced NSCLC patients. Methods: Patients diagnosed with advanced stage NSCLC that treated with Immune checkpoint inhibitors (ICIs) at Shandong Cancer Hospital between March 2019 and January 2021 were enrolled in this study. Peripheral blood samples from these patients were collected to detect BIM-del by polymerase chain reaction. Cox proportional hazards models were used to analyze the clinical outcomes of patients with and without BIM-del. Results: A total of 61 patients with advanced NSCLC who received immunotherapy were enrolled, only 18.0% (11/61) patients were detected with BIM-del. Most of the patients were male (73.8%, 45/61), younger than 65 years (72.1%, 44/61), non- smokers (50.8%, 31/61), previous treatment lines 0-1 (90.2%, 55/61),had Eastern Tumor Cooperative group (ECOG) performance status (PS) 0-1 (98.4%, 60/61). There were no associations between the BIM-del and clinical characteristics. There was no difference in the objective response rate between patients with and without BIM-del (27.3% vs 30 %, p = 1.000).BIM-del is associated with shorter progression-free survival (PFS) (5.7 months vs12.0 months, p = 0.001). The median OS had not been reached. Multivariate analysis suggested that BIM-del was an negative independent prognostic factor for PFS in immunotherapy patients with non-small cell lung cancer, but not for OS. Conclusions: BIM-del may be a negative prognostic biomarker for patients with advanced NSCLC treated with immunosuppressive therapy. It is very important to find effective and accurate biomarkers to predict the PD-1/PD-L1 inhibitors Treatment efficacy, and further exploration is needed in the future.

Bim may be a poor prognostic biomarker in breast cancer patients especially in those with luminal A tumors

Biomarker Discovery To Improve Prediction Of Breast Cancer Survival: Using Gene Expression Profiling, Meta-Analysis, And Tissue Validation

Performing Data Mining to Explain the Correlation between the BIRC5 Gene and Prognosis in Breast Cancer Patients

Expression and clinical significance of Bmi-1 in colorectal cancer

[Association of Bmi-1 Expression with Clinicopathological Features and Prognosis of Colorectal Cancer].

[Expression and Significance of Bmi-1 and Ki67 in Colorectal Carcinoma Tissues].

The association between BIM deletion polymorphism and treatment efficacy of PD-1/PD-L1 inhibitors in advanced NSCLC.

Prognostic Significance of Apoptosis Related Gene Family Bcl-2 in Human Breast Cancer

Expressions of Progesterone Receptor a and B in Breast Invasive Ductal Carcinoma and Their Clinical Significance

Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients

Analysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese non-small cell lung cancer patients.

Prognostic and Clinicopathological Significance of Cyclin B Expression in Patients with Breast Cancer A Meta-Analysis

Significance of Apoptosis and Apoptotic-Related Proteins, Bcl-2, and Bax in Primary Breast Cancer.

The Effect of BIM Deletion Polymorphism on Intrinsic Resistance and Clinical Outcome of Cancer Patient with Kinase Inhibitor Therapy

Combined Use of cyclinD1 and Ki67 for Prognosis of Luminal-Like Breast Cancer Patients

Exploratory Cohort Study and Meta-Analysis of BIM Deletion Polymorphism in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small-cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Cyclin A2 and Ki-67 proliferation markers could be used to identify tumors with poor prognosis in African American women with breast cancer

The Relationship Between BIM Deletion Polymorphism and Clinical Significance of Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy: a Meta-Analysis.

Identification of Tumor Microenvironment-Related Prognostic Biomarkers in Luminal Breast Cancer

Estrogen Receptor Α-Coupled Bmi1 Regulation Pathway in Breast Cancer and Its Clinical Implications

Correlation of BUB1 and BUB1B with the development and prognosis of endometrial cancer